What Compass Pathways’ Phase 3 trial results could mean for patients with depression.
The recent Phase 3 clinical trial results from Compass Pathways and its investigational psilocybin therapy COMP360 mark what could become a pivotal inflection point in the treatment of depression — particularly for individuals living with treatment-resistant depression (TRD).
According to recent reporting in Forbes, Compass has now met the primary endpoints in two large Phase 3 trials evaluating COMP360 for TRD. Patients receiving the therapy demonstrated statistically significant reductions in depressive symptoms compared with control groups. These results position the company to request a formal meeting with the U.S. Food and Drug Administration (FDA) and begin a rolling submission of data, with the goal of filing a full New Drug Application (NDA) later this year.
If approved, COMP360 could become the first FDA-approved psilocybin-based medicine for depression — a milestone that would represent a structural shift in psychiatric pharmacotherapy.
Importantly, COMP360 previously received the FDA’s Breakthrough Therapy designation, a regulatory pathway designed to expedite development and review of treatments that show substantial improvement over existing options. While this designation does not guarantee approval, it signals regulatory recognition of the therapy’s potential clinical significance.
What This Could Mean for Patients
1. Faster Symptom Relief
Traditional antidepressants often require several weeks to achieve meaningful improvement. In contrast, psilocybin-assisted therapy has demonstrated rapid reductions in depressive symptoms in multiple clinical studies — sometimes within days of administration.
2. Potentially Durable Effects
Across earlier trials in both TRD and major depressive disorder (MDD), therapeutic benefits have persisted for months following one or a small number of supervised sessions. This durability contrasts with conventional daily pharmacotherapy, which typically requires continuous dosing.
3. A Fundamentally Different Treatment Model
If approved, COMP360 would not resemble a take-home prescription. Instead, treatment would likely involve:
A controlled clinical setting
Structured psychological preparation
Supervised dosing
Integration therapy afterward
The therapeutic model recognizes that the psychedelic experience — combined with structured psychological support — is integral to clinical outcomes. This represents a paradigm shift from chronic symptom management toward episodic, intervention-based care.
Broader Momentum in Psychedelic Psychiatry
Compass is not alone. Other biotech firms and academic institutions are advancing next-generation psychedelic compounds through late-stage development.
For example, Cybin is developing CYB003, a deuterated psilocybin analogue currently in Phase 3 trials for major depressive disorder. Molecular modifications aim to optimize pharmacokinetics and potentially enhance tolerability or consistency of effect.
Additionally, a landmark Phase 3 trial of MM120 — an LSD-derived compound developed by MindMed — demonstrated that a single supervised dose significantly reduced anxiety symptoms in adults with generalized anxiety disorder. Higher doses produced clinically meaningful improvements compared with placebo, with effects lasting weeks post-treatment. This study further reinforces the broader therapeutic potential of psychedelic-assisted modalities beyond depression.
Collectively, these developments reflect a sustained resurgence in psychedelic-assisted therapies. Dozens of active clinical programs are now targeting TRD, MDD, PTSD, anxiety disorders, and substance use disorders — signaling a reconfiguration of psychiatric drug development pipelines after decades of incremental innovation.
Closing Reflection
The positive Phase 3 data for COMP360 suggest that psilocybin-assisted therapy may be closer than ever to regulatory approval for depression. If the FDA determines that the benefit-risk profile supports approval, patients who have exhausted conventional antidepressant options could soon have access to an evidence-based alternative that integrates pharmacology with structured psychotherapy.
For a population where unmet need remains substantial, this moment could represent not just a new drug approval — but the beginning of a new therapeutic framework in mental health care.